This is the eighth FDA clearance Propeller Health has received for its respiratory therapy platform. Propeller had previously earned the CE Mark in Europe and approval by Health Canada to sell the ...

The Food and Drug Administration (FDA) has approved Breo Ellipta (fluticasone furoate/vilanterol) for the once-daily treatment of asthma in patients aged 18 years and older. The approval of the ...

Propeller Health announced that the Food and Drug Administration (FDA) has granted clearance for its Propeller platform for use with GlaxoSmithKline's Ellipta inhaler, the Company's patented dry ...

Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company developing inhaled therapeutics for pulmonary and ...

Trelegy Ellipta is the first once-daily single inhaler triple therapy to be approved in Europe. It is a combination of an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA) and a ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

If a person has a Medicare Part D prescription drug plan, it may cover the costs of Trelegy Ellipta inhalers. Although out-of-pocket costs can vary by plan ...

New asthma indication for Trelegy Ellipta introduces an important option for patients to the current treatment paradigm The FDA-approved strength for both COPD and asthma is fluticasone furoate / ...

Anoro Ellipta is a brand-name inhaler that’s prescribed for long-term chronic obstructive pulmonary disease (COPD) treatment. Anoro Ellipta contains the active ingredients vilanterol and umeclidinium.

LONDON--(BUSINESS WIRE)--GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has ...

Medicare Part D prescription drug plans may cover Trelegy Ellipta inhalers. Out-of-pocket costs can vary by plan and insurer, but you may only have to pay a 25% ...